First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours

NCT06795022 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

304

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: AZD9793 Intravenous (IV) monotherapy
DRUG: AZD9793 Subcutaneous (SC) monotherapy

Sponsor

AstraZeneca